Siteone Therapeutics Inc. has provided details on the discovery of highly selective, potent, state-independent inhibitors of Nav1.7, a nonopioid target for the potential treatment of pain. While prior Nav1.7 inhibitors appear to bind the inactivated state preferentially, it was hypothesized that superior efficacy would be achievable by engaging all states/conformations of the channel.

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified sodium channel protein type 10 subunit α (Nav1.8) channel blockers reported to be useful for the treatment of treatment of pain, Charcot-Marie-Tooth disease, urinary incontinence, multiple sclerosis and arrhythmia.

Xgene Pharmaceutical Pty Ltd., a subsidiary of Xgene Pharmaceutical Co. Ltd., has received approval in Australia to initiate a phase I trial of the selective TRPM8 blocker XG-2002 (RQ-00434739).

U.S. Department of Health and Human Services has described opioid receptor modulators reported to be useful for the treatment of pain.

Mainline Biosciences (Shanghai) Co. Ltd. has described peptides acting as tachykinin NK1 receptor antagonists reported to be useful for the treatment of pain and opioid dependence.

Ten-eleven translocation 1 (TET1) is a member of the TET family of enzymes that promote DNA...